MX2023004942A - Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades. - Google Patents
Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.Info
- Publication number
- MX2023004942A MX2023004942A MX2023004942A MX2023004942A MX2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A MX 2023004942 A MX2023004942 A MX 2023004942A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- treatment
- bicyclic compounds
- compounds
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108660P | 2020-11-02 | 2020-11-02 | |
| PCT/US2021/057563 WO2022094400A1 (en) | 2020-11-02 | 2021-11-01 | Bicyclic compounds and uses thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004942A true MX2023004942A (es) | 2023-07-06 |
Family
ID=81384389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004942A MX2023004942A (es) | 2020-11-02 | 2021-11-01 | Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240025903A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4236944A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7884275B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230104191A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116568301A (cg-RX-API-DMAC7.html) |
| AR (1) | AR124637A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021371026A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3196582A1 (cg-RX-API-DMAC7.html) |
| CL (2) | CL2023001195A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302465A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004942A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI918751B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022094400A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313039A (en) * | 2021-12-17 | 2024-07-01 | Athira Pharma Inc | Uses of bicyclic compounds for the treatment of diseases |
| KR20250005323A (ko) * | 2022-05-04 | 2025-01-09 | 아티라 파마, 인코포레이티드 | 신경병증을 치료하는 방법 |
| US20250275976A1 (en) * | 2022-05-04 | 2025-09-04 | Athira Pharma, Inc. | Methods of Treating Neuroinflammatory Conditions |
| JP2025538382A (ja) | 2022-11-18 | 2025-11-28 | アティラ・ファーマ・インコーポレイテッド | 炎症病態を治療する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| WO2004035587A1 (en) | 2002-10-17 | 2004-04-29 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
| US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| WO2006036981A2 (en) * | 2004-09-28 | 2006-04-06 | Angion Biomedica Corp. | Small molecule modulators of cytokine activity |
| US7879898B1 (en) * | 2006-02-14 | 2011-02-01 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease |
| EP1947085A1 (en) * | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| US8691819B2 (en) * | 2008-10-14 | 2014-04-08 | Prism Biolab Corporation | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions |
| US20160074400A1 (en) * | 2012-08-06 | 2016-03-17 | University Of Southern California | Wnt modulators for the protection, mitigation and treatment of radiation injury |
| EP3366687B1 (en) * | 2015-09-18 | 2020-04-29 | National University Corporation Tottori University | Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis |
-
2021
- 2021-11-01 AU AU2021371026A patent/AU2021371026A1/en active Pending
- 2021-11-01 EP EP21887720.7A patent/EP4236944A4/en active Pending
- 2021-11-01 US US18/032,918 patent/US20240025903A1/en active Pending
- 2021-11-01 MX MX2023004942A patent/MX2023004942A/es unknown
- 2021-11-01 TW TW110140600A patent/TWI918751B/zh active
- 2021-11-01 JP JP2023551946A patent/JP7884275B2/ja active Active
- 2021-11-01 IL IL302465A patent/IL302465A/en unknown
- 2021-11-01 AR ARP210103033A patent/AR124637A1/es unknown
- 2021-11-01 KR KR1020237018061A patent/KR20230104191A/ko active Pending
- 2021-11-01 CN CN202180079749.8A patent/CN116568301A/zh active Pending
- 2021-11-01 CA CA3196582A patent/CA3196582A1/en active Pending
- 2021-11-01 WO PCT/US2021/057563 patent/WO2022094400A1/en not_active Ceased
- 2021-11-01 CN CN202411623883.1A patent/CN119684295A/zh active Pending
-
2023
- 2023-04-26 CL CL2023001195A patent/CL2023001195A1/es unknown
-
2024
- 2024-02-02 CL CL2024000340A patent/CL2024000340A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4236944A1 (en) | 2023-09-06 |
| TWI918751B (zh) | 2026-03-21 |
| CL2024000340A1 (es) | 2024-08-16 |
| CN116568301A (zh) | 2023-08-08 |
| US20240025903A1 (en) | 2024-01-25 |
| CN119684295A (zh) | 2025-03-25 |
| CA3196582A1 (en) | 2022-05-05 |
| AU2021371026A1 (en) | 2023-06-15 |
| JP2023550543A (ja) | 2023-12-01 |
| AU2021371026A9 (en) | 2024-04-18 |
| JP7884275B2 (ja) | 2026-07-03 |
| KR20230104191A (ko) | 2023-07-07 |
| AR124637A1 (es) | 2023-04-19 |
| IL302465A (en) | 2023-06-01 |
| CL2023001195A1 (es) | 2023-10-20 |
| TW202233622A (zh) | 2022-09-01 |
| EP4236944A4 (en) | 2024-09-04 |
| WO2022094400A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006123A (es) | Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo. | |
| MX2022010425A (es) | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| EP4620469A3 (en) | Tricyclic urea compounds as jak2 v617f inhibitors | |
| EP4438114A3 (en) | Methods of making bempedoic acid and compositions of the same | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MY207223A (en) | Prodrug modulators of the integrated stress pathway | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2021011488A (es) | Compuestos y usos de estos. | |
| MX2025005941A (es) | Moduladores de la actividad tnf-\03b1 | |
| MX2025002953A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis | |
| MX2022006807A (es) | Análogos de rapamicina y usos de estos. | |
| PH12022500021A1 (en) | Il-17a modulators | |
| MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
| MY140169A (en) | Compounds, compositions, and methods | |
| MX2021007948A (es) | Inhibidores de proteina de activacion de fibroblastos. | |
| MX2022000712A (es) | Moduladores de nlrp3. | |
| MX2024011254A (es) | Moduladores de nlrp3 | |
| CR20230408A (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
| MX2025007184A (es) | Triterpenoides sinteticos heteroaromaticos sustituidos polarmente en c17, y metodos de uso de los mismos | |
| MX2022011576A (es) | Moduladores de nlrp3. | |
| WO2020154571A8 (en) | Compounds and uses thereof | |
| CR20240447A (es) | Compuestos de urea tricíclica como inhibidores de v617f de jak2. | |
| EP4357334A3 (en) | Conjugated oligonucleotide compounds, methods of making and uses thereof | |
| MX2024007220A (es) | Psicoplastogenos de pirrolidina fusionada y sus usos. |